NCT04665765View on ClinicalTrials.gov

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

January 18, 2021

Primary Completion Date

July 26, 2022

Study Completion Date

July 1, 2026

Conditions
Diffuse Large B-Cell Lymphoma UnclassifiableRecurrent Diffuse Large B-Cell LymphomaRecurrent Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRecurrent Transformed B-Cell Non-Hodgkin LymphomaRefractory Diffuse Large B-Cell LymphomaRefractory Primary Mediastinal (Thymic) Large B-Cell Cell LymphomaRefractory Transformed B-Cell Non-Hodgkin Lymphoma
Interventions
DRUG

Carboplatin

Given IV

DRUG

Etoposide

Given IV

DRUG

Ifosfamide

Given IV

DRUG

Polatuzumab Vedotin

Given IV

BIOLOGICAL

Rituximab

Given IV

Trial Locations (2)

30322

Emory University, Atlanta

91010

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER